When Better Results Mean Different Rules
A bladder cancer gene therapy showed a 62% complete response rate at six months in patients enrolled after enGene revised its trial protocol in late 2024, compared to a 41% rate in patients who entered the study before the changes. The protocol amendment included three substantive changes to the LEGEND Phase II trial: mandatory tumor re-resection for T1 disease before treatment began, allowance for patients to receive reinduction therapy if initial treatment failed, and a shift toward requiring biopsy confirmation before removing patients from the efficacy analysis.
Under the original protocol, 31 patients showed a 41% complete response rate at six months. Under the amended protocol, 62 patients showed a 62% rate at the same timepoint. Four patients converted to complete response after receiving reinduction therapy by the six-month mark, according to data enGene released this month. The company plans to submit its Biologics License Application in the second half of 2026 and expects approval in 2027, with a patient-based revenue forecast of $731 million by 2033 in a bladder cancer market projected to grow from $3 billion in 2023 to $16 billion by 2033.
The Regulatory Process
enGene will engage with the FDA on a statistical analysis plan to determine "the final efficacy evaluable population." The company holds both Regenerative Medicine Advanced Therapy and Continuous Development Review Program designations, FDA pathways designed to accelerate development for serious diseases with unmet needs.
The trial targets BCG-unresponsive non-muscle invasive bladder cancer. Complete response in this context means no detectable tumor on biopsy and cytology. The amended protocol enrolled 125 patients total, exceeding its target by 25%, and includes 45 high-risk patients with carcinoma in situ who were exposed to BCG but didn't receive adequate treatment, plus 36 BCG-unresponsive patients with papillary-only disease.
The safety profile remained consistent across protocol versions: 42% of patients experienced treatment-related adverse events, with most graded as mild to moderate. Three patients suffered Grade 3 events, but there were no Grade 4 or 5 adverse events, and only 1.6% of patients interrupted dosing while 0.8% discontinued treatment due to adverse events.
Protocol Changes
T1 re-resection, removing residual tumor tissue before gene therapy begins, addresses incomplete initial tumor removal. This procedure means patients enter therapy with different baseline conditions between the pre-amendment and post-amendment cohorts.
The reinduction allowance permits patients who showed no response at three months to receive another round of therapy. In the post-amendment cohort, patients achieving complete response after reinduction therapy by six months are counted as successes. In the pre-amendment cohort, such patients would likely have been classified as treatment failures.
The protocol also requires biopsy confirmation before removing patients from the evaluable population. A patient with ambiguous results under the post-amendment protocol remains in the analysis until definitive biopsy evidence is available.
Approval Timeline
enGene expects 12-month durability data in the second half of 2025 and a pivotal cohort update in the second half of 2026, before the planned BLA submission. The pre-amendment cohort showed a 55% complete response rate at any time, compared to 63% post-amendment. All five patients who reached the nine-month assessment showed complete response, though the sample size is limited. The company has cash runway into the second half of 2028.
GlobalData's $731 million revenue forecast for 2033 assumes approval and commercial success in a market growing at 18% annually. The BLA submission in the second half of 2026 will include efficacy data from patients who haven't yet reached their 12-month assessments.
Protocol Amendments in Drug Development
Protocol amendments occur in roughly one-third of oncology trials. The FDA permits amendments because changes to dosing, patient selection, or endpoint measurement can address design issues identified during development. The flexibility enables course corrections but also means that pre-amendment and post-amendment patient cohorts may not be directly comparable.
The 41% to 62% difference in six-month complete response rates between protocol versions reflects different patient populations and treatment protocols. Patients who achieved complete response after reinduction therapy did not have detectable tumors under the post-amendment protocol, while the original protocol did not include this treatment option.
The FDA's accelerated pathways exist for serious diseases with unmet needs. Statistical analysis plan negotiations are standard procedure for complex trials. The BLA submission will include interim results, which is common in accelerated pathways where conditional approval comes first and confirmatory data follows.
```